№ 122 · biology

Stem cells: what makes them special, why they are fought over, and what 2030 holds

A reader asked: will we see stem cell therapy and healing on a large scale by 2030? The short answer from the sources is: for blood, stem cell transplants are already in use. For almost everything else, the trials are real, small and early. Meanwhile, the FDA warns, clinics widely sell "stem cell" treatments that are not approved. To see why, you need two things most coverage skips: what makes a stem cell special, and why the subject became a fight.

Two powers, not one

Most cells in your body are finished. A heart muscle cell beats, a nerve cell signals, a red blood cell carries oxygen, and none of them normally divides to make more of its kind. A stem cell is defined by two abilities together. The first is self-renewal: it can divide many times and still leave stem cells behind. The second is potency: some of its offspring can turn into specialised cells that it is not itself. The NIH lists three possible outcomes when a stem cell divides: two stem cells, one stem cell and one more specialised cell, or two more specialised cells.

Either power alone is ordinary. A cell that only specialises uses itself up. A cell that only copies itself is just growth, and uncontrolled copying is what a tumour does. A stem cell pool lasts because, over time, its divisions balance: on average each stem cell leaves one stem cell behind. The NIH says plainly that what sets this balance in a living tissue is not yet well known. The lower half of the figure is a toy that shows why the balance matters.

How much a cell can become

Potency comes in degrees. A cell from the inner part of a very early embryo, at the stage before it would implant in the womb, is pluripotent: it can give rise to every cell type of the adult body. Human embryonic stem cell lines were first grown in 1998. Adult stem cells, which the NIH also calls somatic stem cells, sit in particular tissues and make that tissue's cells. A blood-forming stem cell in bone marrow makes red and white blood cells, not neurons. In 2007 researchers reported a third kind for human cells: an ordinary adult body cell reprogrammed in the lab into a pluripotent state. These are induced pluripotent stem cells, or iPS cells.

Interactive Top: pick a starting cell and see which cell types it can give rise to. Bottom: set how a pool of stem cells divides, and watch whether the pool lasts, runs out or runs away.

embryonic stem cell induced (iPS) cell adult body cell lab reprogramming blood-forming stem nerve cell heart muscle cell insulin-making cell retina support cell red blood cell white blood cell

Embryonic stem cell: pluripotent. It can give rise to every cell type on this map, and in principle to every cell type in the adult body.

Our own drawings, not figures from any source. The map shows a few examples, not every cell type, and stops at the first specialised step. Which cells an embryonic or iPS cell can become, and that a blood-forming stem cell makes blood cells but not nerve cells, follow the NIH's Stem Cell Basics; the four target cell types on the right are ones Kirkeby, Main and Carpenter (2025) name as made from pluripotent cells. The pool below is a toy, not a model of any real tissue: 100 stem cells, every one divides once per round, and each division gives two stem cells, one of each, or two specialised cells, in the shares you set (the rest are one of each). The pool is then multiplied each round by one plus the first share minus the second. The vertical scale is logarithmic: each grid line is ten times the one below it.

Why "a cell that heals" is the wrong picture

Popular coverage often treats a stem cell as a kind of medicine that finds damage and repairs it. That is not what the biology offers. A stem cell is raw material. To treat a disease, the NIH lists what transplanted cells must reliably do: multiply enough to replace what was lost, turn into the right cell type, survive in the patient, connect with the tissue around them, escape the patient's immune system, and keep working for the rest of the patient's life. Every item on that list is a separate problem, and a therapy has to solve all of them at once, for one particular cell type in one particular organ.

This is also why there is no single "stem cell therapy". Replacing the cells that support the retina, the nerve cells lost in Parkinson's disease and the insulin-making cells lost in type 1 diabetes are three different products, each with its own trials. Kobold and colleagues (2023) list all three among the diseases that trials of pluripotent-cell products target.

Where the fight came from

The controversy is about where pluripotent cells come from. Deriving a new embryonic stem cell line destroys the early embryo it comes from. The NIH's 2009 funding guidelines drew the line in a way that shows the shape of the argument. Federal money may pay for research on embryonic stem cell lines made from embryos created by IVF for reproduction, no longer needed for it, and donated with consent and without payment. It may not pay for deriving the lines, because that step destroys an embryo; a rule renewed in each year's federal budget, the Dickey Amendment, forbids it. The draft guidelines drew about 49,000 public comments, from patient groups, scientists and religious organisations among others.

iPS cells were welcomed partly because they skip the embryo. They have not settled the matter entirely: they are pluripotent too, so the ISSCR's 2021 guidelines, written by a 45-member task force chaired by Robin Lovell-Badge, still set limits on what may be done with pluripotent cells and embryos. Research that grows human embryos in a dish, for example, needs specialist review even up to 14 days or the first sign of a body axis, whichever comes first. The 2021 update took going past that line off the banned list, but asks for public discussion before any review committee considers it. Human reproductive cloning is on the "not allowed" list.

Hype against evidence

The second fight is newer. The ISSCR guidelines note that in the five years before 2021, stem cell trials grew, and so did "inappropriate uses and exaggerated or false claims". They warn against selling unproven treatments early, and they say a product should be authorised only on substantial evidence from properly controlled trials. A patient registry, they add, is no substitute for such a trial, and some registries seem to be used as advertising.

The US Food and Drug Administration is blunter. Its consumer page says clinics broadly market unapproved stem cell and related products for a wide range of conditions. It lists reported harms including blindness, tumour formation and infections. It says no such therapy has been approved for any neurological disorder, heart or lung disease, or orthopaedic condition such as knee or back pain. The same page, last updated in April 2024, says the only approved stem cell products in the US were blood-forming cells from umbilical cord blood, for disorders of the blood-making system. The FDA's list of approved cell and gene products has grown since: in December 2024 it added Ryoncil, for children with a severe transplant complication, graft-versus-host disease, that steroids have not controlled.

So, by 2030?

Stem cell treatment is already in use for one tissue: blood. Blood-forming stem cells from cord blood, and from bone marrow, rebuild a patient's blood-making system, and the FDA has licensed several cord blood products for that.

For replacing other tissues, count the evidence. Kirkeby, Main and Carpenter (2025) counted 115 approved clinical trials worldwide of products made from pluripotent cells, as of December 2024, testing 83 products. More than 1,200 patients had been dosed. That averages about ten people per trial, by our arithmetic, and the review found no safety concern that applied across products. Most trials target the eye, the brain and spinal cord, and cancer. A 2023 count by Kobold and colleagues found 109 pluripotent-cell studies in 14 countries. The median time from a study's start to its planned completion was 7 years, and for the eye-disease studies, published results did not yet allow a pooled analysis of outcomes. They also found the field has moved from embryonic lines towards iPS cells since 2018.

Our reading of those numbers: by 2030 some of these products may reach approval for specific conditions, and eye disease has the most trials behind it. But a study started today and running the median seven years would finish after 2030. "Healing on a large scale", across many diseases, is not what the trial record points to by then. Anyone offering it sooner, for a fee, is what the FDA and the ISSCR are warning about.

In one breath

A stem cell is special because it can both copy itself and become other cells, and it matters which: embryonic and iPS cells can become anything, adult stem cells mostly their own tissue. The fight is over embryos, and now over clinics selling what trials have not shown. Blood stem cell transplants are already in use. For other tissues, the sources point to a few first approvals by 2030 at most, not general healing.

Where this comes from

  1. Stem Cell Basics linked only, not reproduced
    National Institutes of Health, Stem Cell Information · 2016
    stemcells.nih.gov/info/basics/stc-basics
  2. National Institutes of Health Guidelines for Human Stem Cell Research linked only, not reproduced
    National Institutes of Health (Raynard S. Kington, Acting Director) · 2009
    stemcells.nih.gov/research-policy/guidelines-for-human-stem-cell-research
  3. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update (Stem Cell Reports 16(6):1398-1408) linked only, not reproduced
    Robin Lovell-Badge, Eric Anthony, Roger A. Barker, Tania Bubela, Ali H. Brivanlou, Melissa Carpenter et al. (ISSCR Guidelines Task Force, 45 authors) · 2021
    pmc.ncbi.nlm.nih.gov/articles/PMC8190668/
  4. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update (Cell Stem Cell 32(1):10-37) linked only, not reproduced
    Agnete Kirkeby, Heather Main, Melissa Carpenter · 2025
    doi.org/10.1016/j.stem.2024.12.005
  5. History and current status of clinical studies using human pluripotent stem cells (Stem Cell Reports 18(8):1592-1598) linked only, not reproduced
    Sabine Kobold, Nils Bultjer, Glyn Stacey, Sabine C. Mueller, Andreas Kurtz, Nancy Mah · 2023
    pmc.ncbi.nlm.nih.gov/articles/PMC10444540/
  6. Important Patient and Consumer Information About Regenerative Medicine Therapies (updated 8 April 2024) linked only, not reproduced
    US Food and Drug Administration, Center for Biologics Evaluation and Research · 2021
    www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
  7. Approved Cellular and Gene Therapy Products (list current as of 17 September 2026) linked only, not reproduced
    US Food and Drug Administration, Office of Therapeutic Products · 2026
    www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products